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Introduction {#sec1}
============

Generation of functional organs from pluripotent stem cells (PSCs) is one of the ultimate goals of regenerative medicine. In addition to the *in vitro* approaches, such as organoid culture and organ-fabrication ([@bib9], [@bib16], [@bib17], [@bib29], [@bib30], [@bib31], [@bib33], [@bib32], [@bib42]), an alternative *in vivo* strategy has been proposed. This strategy originally proposed by [@bib13] uses an organogenesis-disabled animal and a blastocyst complementation technique. They generated an interspecies chimera by introducing rat induced pluripotent stem cells (iPSCs) into mouse embryos with a *Pdx1*^−/−^ mutation that had caused a pancreatogenesis-disabled phenotype and succeeded in creating a mouse with the pancreas of a rat. These results were interpreted as follows----an intra-embryonic environment lacking endogenous pancreatic cell lineage allowed the exogenous rat iPSCs to colonize in an empty developmental niche to form a xenogeneic pancreas in the mouse body ([@bib13], [@bib26]).

This approach is endorsed by the notion that *in vitro* generation of human organs with complex function and structure is extremely difficult ([@bib26]), and organ development from PSCs in the natural physiological environment of a xenogeneic fetus would be better supported. Recent studies have been demonstrated compelling evidence for blastocyst complementation in rodents by generating organs, such as kidney, brain, vessels, and blood ([@bib4], [@bib7], [@bib13], [@bib19], [@bib22], [@bib26], [@bib35], [@bib39], [@bib40]).

To fulfill the ultimate aim of generating human organs in an animal body, the use of large animals is essential. We, therefore, established a blastocyst complementation system in pigs ([@bib19]). At present, we have demonstrated the production of genetically modified pigs with a pancreatogenesis-disabled phenotype and proved that the missing organ could be restored by exogenous cells through allogenic blastocyst complementation ([@bib19]). The concept of blastocyst complementation that chimerizes a cloned dysorganogenetic embryo with functionally normal pluripotent cells needs to be verified for applicability to multifarious organs in pigs to determine the potential value of the technology in the medical setting.

In our previous study ([@bib19]), the apancreatic phenotype was induced in pigs by the overexpression of a transgene (mouse *Pdx1-Hes1*: hairy and enhancer of split-1 gene driven by pancreatic and duodenal homeobox 1 gene promoter). In recent years, gene knockout (KO) by genome editing has significantly advanced its feasibility and practical applicability in mammals ([@bib5], [@bib34]). Thus, knocking out the master regulator gene of a specific organ has become a straightforward method for generating the dysorganogenetic phenotype ([@bib4], [@bib7], [@bib13], [@bib35], [@bib36]). Direct genome editing for zygotes, however, has been reported to result in mosaic mutations ([@bib36]), which hinder obtaining conclusive evidence for blastocyst complementation. We, therefore, used, in this study, a somatic cloning technique using nuclear donor cells carrying a defined loss-of-function mutation to produce host embryos with an organogenesis-disabled trait for blastocyst complementation.

We aimed at investigating the efficiency of genetic modification by genome editing in pigs to give rise to an organogenesis-disabled phenotype in various organs, including pancreas, kidney, liver, and blood vessels. We also verified the feasibility of blastocyst complementation for compensating the disabled organogeneses.

Results {#sec2}
=======

Apancreatic Phenotype Generated by *PDX1*-KO and Restoration of Normal Pancreatogenesis by Blastocyst Complementation {#sec2.1}
---------------------------------------------------------------------------------------------------------------------

In our previous study ([@bib19]), we demonstrated that an apancreatic phenotype in pigs could be achieved by overexpressing the mouse *Pdx1-Hes1* transgene. In this study, we knocked out porcine endogenous *PDX1* gene, based on previous reports demonstrating apancreatic phenotype caused by *Pdx1*^−/−^ mutation in rodents ([@bib8], [@bib13], [@bib25]) and pigs ([@bib10]).

Porcine fetal fibroblast cells (male) carrying TALEN-induced biallelic mutations in exon 1 of *PDX1* were used for somatic cell nuclear transfer (SCNT) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Two types of cloned embryos were generated from two lines of nuclear donor cells with different mutation types ([Figure S1](#mmc1){ref-type="supplementary-material"}B), and these cloned embryos were transferred together to a recipient gilt ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Analysis of four cloned fetuses recovered at mid-gestation (day 55) revealed that both the *PDX1*-KO mutations gave rise to apancreatic phenotypes ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}C).Figure 1Apancreatic Phenotype of the *PDX1*^−/−^ Fetus and Restoration of Pancreatogenesis by Blastocyst Complementation(A) Apancreatic phenotype of a *PDX1*^−/−^ cloned fetus at mid-gestation (day 55; WT, day 66).(B) Chimeric full-term fetuses (three left animals in upper panels) and restored pancreata (lower panels). Fetuses exhibiting huKO fluorescence and male phenotype were determined as chimeras. Chimeric fetuses (^∗^) indicating higher level of systemic chimerism showed well-restored pancreata (leftmost in lower panels), while development of pancreatic tissue was poor in a fetus with lower chimerism (center in lower panels). The rightmost animal in upper panels (\#) presents a *PDX1*-KO fetus showing typical features of the apancreatic phenotype (lower panels).(C) Histological features of the pancreatic tissue generated by blastocyst complementation. Upper panels: H&E-stained sections. Lower panels: sections immunostained for insulin (white), glucagon (green), and huKO (red). Restored pancreatic tissue of the fetus (center) with higher chimerism entirely expressed huKO fluorescence. Scale bars, 100 μm.

Primary cultured fibroblasts were established from the *PDX1*-KO apancreatic fetuses (male) and used for generating cloned embryos as the host embryos for blastocyst complementation. The host *PDX1*-KO embryos at the morula stage were injected, as reported previously ([@bib19]), with donor blastomeres derived from female cloned embryos expressing the fluorescent proteins, Kusabira-Orange (huKO) ([@bib20]) or Plum ([@bib37]). Transfer of 325 complemented embryos at the blastocyst stage to the uterus of four recipients resulted in three pregnancies, which allowed us to analyze ten full-term fetuses comprising four chimeric and six non-chimeric animals ([Table S1](#mmc1){ref-type="supplementary-material"}). Chimerism was proven by phenotypic features (phenotypically male individuals expressing huKO or Plum) ([@bib21]) or genotyping ([Figure 1](#fig1){ref-type="fig"}B). Two of the chimeric fetuses showed normally developed pancreata. The restored pancreata entirely expressed huKO fluorescence ([Figures 1](#fig1){ref-type="fig"}B and 1C), indicating that they were derived from exogenous cells. The restored pancreatic tissue demonstrated normal histological features, including endocrine and exocrine cells.

However, two of the chimeric fetuses possessed less-developed pancreata ([Figures 1](#fig1){ref-type="fig"}B and 1C). The proportion of the exogenous cells in these chimeric fetuses was lower ([Figure 1](#fig1){ref-type="fig"}B), suggesting that the restoration of the *PDX1*-KO apancreatic trait required chimerism with exogenous *PDX1*^+/+^ cells in high density in the pancreatogenic progenitor tissue.

Vasculogenesis-Disabled Phenotype Generated by Kinase Insert Domain Receptor-KO and Restoration of Normal Vessels by Blastocyst Complementation {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------------------------

Previous studies ([@bib13], [@bib35], [@bib40]) have revealed that blood vessels had been developed from both donors and host animal-derived cells in the restored organ generated by blastocyst complementation in apancreatic and anephrogenic animals. For clinical transplantation of an organ generated in a host animal by means of interspecies blastocyst complementation, it is necessary to replace the vasculature with exogenous human cells so that the number of xenogenic component cells derived from the host animal can be minimized.

Vasculogenesis can be disrupted by the deficiency of the *Flk-1* gene in rodents ([@bib28]). Thus, establishing a vasculogenesis-disabled trait in the host animal and restoring the trait by exogenous cells may be a strategy to overcome composite vasculogenesis of the host- and donor-derived cells ([@bib7]). In this study, we, therefore, examined whether deficiency of the *FLK1* ortholog or kinase insert domain receptor (*KDR*) in pigs can cause the vasculogenesis-disabled phenotype as seen in rodents ([@bib27], [@bib28]) and whether the trait can be restored by blastocyst complementation.

Additional *KDR* deficiency was introduced into the *PDX1*-KO fetal fibroblast cells (\#45) using TALEN targeting the exon 1 of the gene ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). The *PDX1/KDR* dual KO cells (male) were used for SCNT to produce cloned fetuses ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Fetuses at the somite stage (days 15--21) showed distinctly retarded development lacking vasculogenesis and blood flow at all embryonic stages observed ([Figures 2](#fig2){ref-type="fig"}A and [3](#fig3){ref-type="fig"}A).Figure 2Vasculogenesis-Disabled Phenotype of *KDR*^−/--^ Fetus and Its Compensation by Blastocyst Complementation(A) A *PDX1/KDR* dual KO (DKO) fetus with vasculogenesis-disabled phenotype (left) and a chimeric fetus with normalized trait (right) obtained after blastocyst complementation.(B) Left: a *PDX1/KDR*-KO fetus showing retarded development without blood flow. Center: the appearance of a chimeric fetus showing systemic chimerism with dense distribution of the exogenous huKO-expressing cells. Right: morphology and fluorescence intensity of a normal fetus derived from the huKO transgenic cell. Scale bars, 1 mm.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.Figure 3Morphological and Histological Features of the *PDX1/KDR* Dual KO Cloned Fetuses and Its Compensation by Blastocyst Complementation(A) Immunohistochemical analysis of *PDX1/KDR* dual KO fetuses and chimeric fetuses with compensated vasculogenesis by blastocyst complementation. Scale bars, 50 μm. Left panels show H&E-stained sagittal section of day 21 fetuses. Top, a *PDX1/KDR* dual KO (DKO); middle, a chimera obtained by blastocyst complementation; bottom, a non-chimeric fetus derived from the huKO-expressing donor blastomeres. Signals of KDR, PECAM1, and CD34 can be seen (DAB stained) on the vascular endothelial cells of the chimera and donor cell (huKO) derived fetuses. On the other hand, neither vascular structure nor endothelial markers were observed in the tissue of the *PDX1/KDR* dual KO fetus.(B) Upper panels: a full-term fetus proven to be chimeric by its phenotypic sex (male) accompanying huKO expression and its restored pancreas entirely expressed huKO fluorescence, indicating that it was generated from the exogenous cells as a result of complementation. Insets show bright-field pictures. Lower panels: the restored pancreatic tissue included well-developed islets stained with α and β cell markers. Scale bars, 100 μm.(C and D) (C) PECAM1-positive (green) endothelial tissue of a splenic blood vessel in the chimeric fetus exhibiting the donor-cell-derived huKO signal (red). (D) Spleen tissue of the chimeric fetus exhibiting double-positive signals of hematopoietic cell marker (CD45, green) and the donor-cell-derived huKO (red). (C and D) A pair of mirror-image sections were stained due to difficulty of double immunohistochemical staining (lower panels, flipped picture). Scale bars, 10 μm (C) and 50 μm (D).

Blastocyst complementation was performed using the *PDX1/KDR*-KO cloned morulae as the host embryos and *in-vivo*-derived morulae expressing huKO as the blastomere donors. Transfer of 38 complemented blastocysts to a recipient gilt resulted in 27 fetuses (day 21), including 9 chimeric and 18 non-chimeric fetuses ([Figure 2](#fig2){ref-type="fig"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). Among the nine chimeric fetuses, five showed normal development, including vasculogenesis and blood flow similar to the normal cloned fetuses ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}A). Four other chimeric fetuses exhibited severe retardation of development, which was typically observed in the *PDX1/KDR*-KO fetuses. Vasculogenesis was scarce in these chimeras, indicating that contribution of normal exogenous cells was limited in their embryo/fetal development.

Then, we examined the full-term development of the chimeric fetuses generated by complementation of the *PDX1/KDR*-KO embryos. The *PDX1/KDR*-KO host embryos were complemented by blastomeres of *in-vivo*-derived or IVF (*in vitro* fertilization)-derived morulae expressing huKO. Transfer of 92 complemented blastocysts to two recipients (one miscarried) gave rise to four full-term fetuses (day 106), including a chimera ([Figure 3](#fig3){ref-type="fig"}B). This chimeric fetus showed well-developed pancreas, including islets identified by endocrine markers ([Figure 3](#fig3){ref-type="fig"}B). Immunohistochemical analysis revealed that endothelial tissue and hematopoietic cells had derived from the donor cells ([Figures 3](#fig3){ref-type="fig"}C and 3D). These results demonstrated that the dual organogenesis-disabled phenotype could be simultaneously rescued by blastocyst complementation.

Anephrogenic Phenotype Generated by Spalt-like Transcription Factor 1-KO and Restoration of Normal Nephrogenesis by Blastocyst Complementation {#sec2.3}
----------------------------------------------------------------------------------------------------------------------------------------------

Homozygous KO of spalt-like transcription factor 1 (Sall1) in rodents was reported in a previous study to induce a nephrogenesis-disabled phenotype ([@bib4], [@bib35]). In this study, we investigated whether *SALL1*-KO in pigs also results in the anephrogenic phenotype and whether blastocyst complementation is effective in restoring the deficient trait.

Two types of porcine fetal fibroblasts harboring biallelic KO mutations in exon 3 of the *SALL1* gene were established using genome editing by ZFN ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Using these cells for SCNT, we obtained five cloned fetuses at day 43 to 66 ([Figure S3](#mmc1){ref-type="supplementary-material"}C). [Figure 4](#fig4){ref-type="fig"}A shows a typical *SALL1*-KO fetus exhibiting impaired nephrogenesis (day 43) accompanying normally developed ureters and urinary bladder. The size of the vestigial kidney tissue varied among the fetuses with the same mutation type ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Histological development of the vestigial *SALL*^−/--^ kidney was severely impaired with structural variations ([Figure 4](#fig4){ref-type="fig"}B). Renal tissues of the *SALL*^−/--^ fetuses mainly comprised of interstitial tissues lacking organized structures. Immunohistochemical analysis detected no SALL1 expression in these tissues ([Figure 4](#fig4){ref-type="fig"}B). On the other hand, ureters and bladders of the *SALL*^−/--^ fetuses exhibited no morphological and histological abnormalities. The most developed case we studied was the anephrogenic phenotype in a fetus at day 66. This fetus, however, appeared to be in the process of being aborted, suggesting lethality of the *SALL1*^−/−^ mutation after the mid-gestation stage.Figure 4Anephrogenic Phenotype of *SALL1*^−/−^ Fetus and Its Compensation by Blastocyst Complementation(A) Anephrogenic phenotype of a *SALL1*^−/−^ cloned fetus at mid-gestation (day 43). WT, kidney of age-matched control.(B) Histological features of the vestigial kidney tissues. Upper panels indicate phenotypic variation in *SALL1*^−/−^ fetuses. Immunostaining of the *SALL1*^−/−^ vestigial kidney (lower right) detected no SALL1 expression. Lower left: SALL1-positive WT tissue. Scale bars, 200 μm.(C) Normally developed kidneys of a chimeric fetus (day 43, left) obtained by blastocyst complementation. Note that the bladder was torn off from the ureter at the time of excising. huKO-tg, normally formed kidneys of a control fetus expressing huKO fluorescence. *SALL1*-KO, deficient renal development of a *SALL1*^−/−^ fetus. Scale bars, 5 mm.(D) Histological features of the kidney tissues (upper panels) from a chimeric fetus produced by blastocyst complementation. Fluorescence expression shown in the upper right panel indicates that renal development in the chimeric fetus is entirely compensated by exogenous cells by blastocyst complementation. Lower panels: renal tissues of a control WT fetus. Scale bars, 100 μm.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We established primary cultured fibroblasts from the cloned mutant fetuses with anephrogenic phenotype and used them as nuclear donors to produce host embryos for blastocyst complementation. The host embryos at the morula stage were complemented with blastomeres of cloned embryos expressing huKO. Transfer of 291 complemented blastocysts to four recipients (three impregnated) resulted in two chimeric and five non-chimeric fetuses ([Table S1](#mmc1){ref-type="supplementary-material"}). Both chimeric fetuses retained impaired kidney development similar to the cloned *SALL1*-KO fetuses ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Distribution of huKO-expressing cells in the hypoplastic kidney tissue was limited ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C), indicating that contribution of exogenous cells in the development of these chimeric fetuses was not enough, hence resulting in the incomplete restoration of nephrogenesis of the *SALL1*-KO embryos. A limited number of the huKO-positive cells were seen in the ureter as well ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

In a reattempt at blastocyst complementation of the *SALL1*-KO cloned embryos, we used donor blastomeres prepared from *in-vivo*-derived or IVF-derived embryos, instead of the cloned embryos ([Table S1](#mmc1){ref-type="supplementary-material"}). Transfer of 97 complemented blastocysts to two recipients (all impregnated) gave rise to 12 fetuses ([Table S1](#mmc1){ref-type="supplementary-material"}), including a chimeric fetus (day 43) that exhibited normally developed kidneys ([Figure 4](#fig4){ref-type="fig"}C). The restored kidney tissue was histologically normal and entirely positive for huKO expression, confirming the role of exogenous cells in nephrogenesis ([Figure 4](#fig4){ref-type="fig"}D).

Ahepatogenic Phenotype Generated by Hematopoietically Expressed Homeobox-KO and Restoration of Normal Hepatogenesis by Blastocyst Complementation {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------------------------

Hex deficiency in rodents is known to cause a hepatogenesis-disabled phenotype ([@bib1]). The aim of the following experiment was to investigate whether hematopoietically expressed homeobox (*HHEX*)-KO in pig also results in an ahepatogenic phenotype and whether blastocyst complementation is effective in restoring the deficient trait. Porcine fetal fibroblasts (PFFs) carrying biallelic KO mutations in exon 1 of the *HHEX* gene were established by TALEN ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Using these cells as nuclear donors for SCNT, cloned fetuses (day 22) were obtained, which exhibited severe developmental retardation, including liver dysplasia ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S5](#mmc1){ref-type="supplementary-material"}C). Varying morphological abnormalities were significant in the anterior portion of the mutant fetuses as previously described for the *Hex*-KO mouse ([@bib1]).Figure 5Ahepatogenic Phenotype of *HHEX*^--/--^ Fetus and Its Compensation by Blastocyst Complementation(A) An *HHEX*^--/--^ fetus with a hepatogenesis-disabled phenotype (left) and a fetus with normalized trait obtained after blastocyst complementation (middle). Scale bars, 5 mm.(B) Transverse section of a *HHEX*^--/--^ fetus (left) with a nearly empty liver capsule-like structure (arrowhead), indicating failure of liver development. A chimeric fetus obtained by blastocyst complementation (center) exhibited normally developed liver as seen in a WT fetus (right). Inset pictures of fetuses indicate directions of the transverse sections (dotted line). Sagittal sections of the *HHEX*^--/--^ (left) and WT (right) fetuses. Scale bars, 500 μm.(C) A chimeric (*HHEX*^--/--^ ↔ *huKO*) full-term fetus with normal hepatogenesis obtained by blastocyst complementation, showing fluorescence derived from the donor cells.(D) Morphologically normal liver developed in the chimeric fetus.(E) Histological features of the liver developed from the exogenous cells. Scale bars, 100 μm.

*HHEX*-KO cloned embryos with ahepatogenic trait were used as the host embryos for blastocyst complementation. Host embryos at the morula stage were complemented using blastomeres from the *in-vivo*-derived morulae. As a result of transferring 37 complemented blastocysts to a recipient gilt, 15 fetuses (day 23), including 4 chimeric and 11 non-chimeric ones were produced ([Table S1](#mmc1){ref-type="supplementary-material"}). Among the four chimeric fetuses, one exhibited organogenesis, including a normal liver ([Figures 5](#fig5){ref-type="fig"}A and 5B). Anatomical features of the restored liver were similar to an age-matched wild-type (WT) fetus. The other three chimeric fetuses showed severe developmental retardation as seen in the *HHEX*-KO fetuses, indicating limited contribution of the exogenous cells to embryogenesis thereby failure in restoring dysplastic hepatogenesis.

We then confirmed the full-term development of the fetuses with complemented hepatogenesis. We produced three chimeric fetuses after the transfer of 95 complemented blastocysts ([Figures 5](#fig5){ref-type="fig"}C; [Table S1](#mmc1){ref-type="supplementary-material"}). The chimeric fetuses obtained were all alive at the time of the cesarean section and development of the liver was normal in all the animals ([Figures 5](#fig5){ref-type="fig"}D and 5E).

Discussion {#sec3}
==========

To overcome organ shortage in organ transplantation therapy, we have advocated a concept of generating human organs from PSCs by organogenesis in xenogenic animals. This concept consists of two fundamental technologies, i.e., induction of an empty developmental niche in the organogenesis of pig fetus and its compensation by exogenous iPSCs through blastocyst complementation. In this study, we proved that disruption of a gene playing a pivotal role in organogenesis could give rise to an organogenesis-disabled trait in pigs not only for the pancreas, but also for the kidney, liver, and blood vessels. We also demonstrated the applicability of the blastocyst complementation technique in an allogenic setting for compensating the dysorganogenetic phenotypes of the pigs.

We revealed, in this study, that knocking out porcine *PDX1* gave rise to an apancreatic phenotype as has been shown in rodents ([@bib8], [@bib13], [@bib25]). In our previous study ([@bib19]), vestigial pancreatic tissue remained in the phenotype induced by *Pdx1*-*Hes1* overexpression. The results of our study, as well as that of [@bib10], showed that the *PDX1*-KO in pig gave rise to a complete apancreatic phenotype while permitting the mutant fetus to develop to full term. To our knowledge, this is the first report demonstrating successful blastocyst complementation in pigs with *PDX1*-KO-induced complete pancreatogenesis-disabled phenotype ([@bib10]).

Blastocyst complementation of the *PDX1*-KO trait, however, could occasionally result in incomplete restoration of the missing pancreata even in chimeric piglets exhibiting overt coat color chimerism. Pancreatic progenitor cells expressing *PDX1* appear in the foregut of the somite stage fetuses ([@bib6]). Dense contribution of exogenous cells in the pancreatic precursor region of the chimeric fetus was probably crucial in determining the fate of pancreatogenesis.

To accomplish successful clinical transplantation of a pig-derived human organ, the presence of porcine tissues, such as blood vessels need to be avoided to prevent xenorejections. We demonstrated for the first time in pigs that generation of host-derived blood vessels could also be replaced by exogenous cells in the *KDR*-KO host embryos for blastocyst complementation. In this study, we additionally knocked out the *KDR* gene of the *PDX1*-KO fetal fibroblast cells. This appears to be a feasible option to add *KDR*-KO to a preexisting cell line carrying other dysorganogenetic mutations.

*Flk-1* null mice have been reported to die between embryonic day E8.5 and E9.5 without any organized blood vessels or yolk sac blood islands ([@bib27], [@bib28]). *KDR-*KO in pigs was also found to be lethal to the embryo at the somite stage around E15 to E17, which corresponds to E8.5/E9.5 in mice ([@bib24]). Thus *KDR*-KO in pigs appeared to become lethal at nearly the same embryonic stage as in the *Flk-1*^−/−^ mice.

Fetuses with restored vasculogenesis generated by complementation of the *PDX1/KDR*-KO embryos were chimeric with a systemically higher contribution of exogenous cells. *KDR* expression is pivotal for the development of multiple tissues that are distributed throughout the whole body, including vascular endothelia, smooth muscles, and hematopoietic cells ([@bib7], [@bib27], [@bib28]). Therefore, dense distribution of exogenous cells throughout the body tissue of the chimeric fetuses may be hardly avoidable when the empty niche of *KDR* deficiency is to be compensated.

Systemic chimerism is also an emerging challenge in compensation of a gene deficiency, such as *HHEX*-KO, which is involved in the dysorganogenesis of multiple organs. *HHEX* plays a pivotal role not only in hepatogenesis, but also in the generation of the thyroid and forebrain ([@bib1], [@bib2], [@bib11]). In the conception of interspecies blastocyst complementation between pigs and humans, the incidence of disordered chimerism involving exogenous human cells needs to be avoided. Developing measures to restrict chimerism ([@bib12]) in the target organ/tissue will be increasingly important.

Deletion of *Sall1* in mice has been reported to cause depletion of nephron progenitors in developing kidney ([@bib23]), thereby resulting in renal agenesis or hypoplasia. Our results demonstrated that *SALL1*^−/−^ in pigs also gave rise to the anephrogenic phenotype. We also demonstrated for the first time in pigs that the anephrogenic phenotype of *SALL1*-KO could be compensated by allogenic blastocyst complementation, as shown in the previous rodent study ([@bib35]).

Our data suggested that the degree of chimerism appeared to be critical for successful compensation of the anephrogenic phenotype. In the chimeric fetuses in which compensation of the *SALL1*^−/−^ anephrogenic phenotype was incomplete, distribution of the donor blastomere-derived cells appeared less in the nephrogenic tissue. Fetal kidneys develop through mutual inductive interaction between the metanephric mesenchyme and the ureteric bud ([@bib23]). Minor populations of normal cells in the nephrogenic progenitor tissues might have failed to ensure nephrogenesis in the *SALL1*^−/−^ ↔ WT chimeras.

During blastocyst complementation for the anephrogenic phenotype in *Sall1*^−/−^ mice, some of the nephric tissues, such as collecting duct and microvascular endothelium, were not entirely replaced by exogenic cells ([@bib35]). These results would imply coexistence of the host-derived cells in the kidney tissue that is generated by interspecies blastocyst complementation. Although residual cells/tissues in the *SALL1*^−/−^ porcine kidney are yet to be examined, additional genetic modifications to the *SALL1*^−/−^ trait would enable high-level elimination of the pig-derived cells ([@bib41]).

Autopsy of four recipient females that conceived the *SALL1*^−/−^ fetuses yielded no anephrogenic fetus that had grown beyond the mid-gestation stage ([Figure S3](#mmc1){ref-type="supplementary-material"}). We conducted a separate study in which the *SALL1*^+/−^ males and females produced by TALEN-mediated genome editing of zygotes were mated with each other. We obtained compelling data indicating lethality of the *SALL1*^−/−^ fetuses around the mid-gestation stage ([@bib38]). Therefore, it is unlikely that the lethality of the *SALL1*^−/−^ fetuses obtained in this study is ascribed to the abnormality of the cloned fetuses. Although involvement of off-target mutations in the *SALL1*^−/−^ fetuses cannot be ruled out, possible influence of *SALL1*-KO in multiple organs/tissues, including brain, limb buds, and heart ([@bib14], [@bib35]), is more likely the cause of fetal lethality in pigs. [@bib35] ascribed neonatal lethality of the *Sall1*-KO mice to a defect in the nervous system causing abnormal suckling function. The reasons for the lethality of the *SALL1*^−/−^ pig fetuses are yet to be investigated.

In our previous study, we obtained a proof-of-concept (POC) for blastocyst complementation that compensates for the apancreatic phenotype of the porcine *Pdx1-Hes1* transgenic embryos. In this study, we demonstrated that the POC could be extended to a wider range of dysorganogenetic phenotypes induced by an alternative genetic modification approach, i.e., genome editing. Although factors hindering interspecies chimerism between humans and pigs is yet to be clarified, blastocyst complementation has been proposed as a means of compensating the empty developmental niche of organogenesis by exogenous-xenogenic pluripotent cells. Strategies that allow the organogenic region of the target organ in a pig fetus to be highly chimeric with the xenogenic cells will be a crucial part of future research. Attempts using chimera-competent porcine embryonic stem cells ([@bib3]) would secure a bridgehead into human-pig blastocyst complementation. At the same time, developing a strategy for cell fate control is also crucial to ensure compensation of the empty developmental niche, while avoiding unwanted systemic chimerism.

Experimental Procedures {#sec4}
=======================

Animal Care and Chemicals {#sec4.1}
-------------------------

All animal experiments in this study were approved by the Institutional Animal Care and Use Committee of Meiji University (IACUC07-0006, 11-0016, 12-0008, 16-0006, 17-0005). All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated.

Design and Preparation of Genome Editing Tools {#sec4.2}
----------------------------------------------

Custom TALEN plasmids targeted to porcine *PDX1*, *KDR*, and *HHEX* genes, and ZFN plasmids targeted to porcine *SALL1* gene, were obtained from ToolGen (Seoul, South Korea) and Sigma-Aldrich, respectively. The design and validation of these TALENs and ZFNs were performed by the manufacturers. For the production of mRNAs encoding TALENs and ZFNs, each of the linearized plasmids were used as templates for *in vitro* transcription. The capped and poly(A)-tailed TALEN and ZFN mRNAs were synthesized using a mMESSAGE mMACHINE T7 Ultra Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer\'s instructions. The TALEN- and ZFN-encoding mRNAs were purified using a MEGAclear Kit (Thermo Fisher Scientific) and suspended in RNase-free water. These genome-editing molecules were stored at −80°C until use.

Establishment of Gene-KO Cells and Culture Conditions {#sec4.3}
-----------------------------------------------------

A primary culture of male PFF cells that was used to establish gene-KO cells was cultured in Minimum Essential Media α (Thermo Fisher Scientific) supplemented with 15% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution (Thermo Fisher Scientific) in type-I collagen-coated dishes or plates (AGC Techno Glass, Shizuoka, Japan), under a humidified atmosphere containing 5% CO~2~ at 37°C. For electroporation, PFF cells were cultured to 70%--90% confluence, washed twice with Dulbecco's PBS (D-PBS(−)) and detached with 0.05% trypsin-EDTA. These cells (5 × 10^5^) were suspended in 50 μL buffer R (included in the Neon Transfection System, Thermo Fisher Scientific) containing 1 μg TALEN or ZFN mRNAs. The cells were then electroporated with a single DC pulse (1,100 V, 30 ms, pulse number 1; program no. 6 for *PDX1-*, *KDR-*, and *SALL1*-KO, and 1,600 V, 20 ms, pulse number 1; program no. 4 for *HHEX*-KO), followed by culture at 32°C for 3 days, without antibiotics for the first 24 h and with antibiotics thereafter. Next, the cells were cultured at 37°C until they reached 90% confluence, after which limiting dilution was performed to obtain single-cell-derived clones in five 96-well plates. Twelve to 14 days later, colonies at high confluence (\>70%) were selected and divided for subculture and mutation analyses.

Analysis of Mutations in Nuclear Donor Cells and Fetuses {#sec4.4}
--------------------------------------------------------

For mutation analysis, the target region of each genome-editing tool was amplified via direct PCR from cell clones using MightyAmp DNA polymerase version 2 (Takara Bio, Shiga, Japan) and then nested PCR was performed using appropriate primers ([Table S2](#mmc1){ref-type="supplementary-material"}). The sequence of the amplicons containing the target region was determined using sequencing primers ([Table S2](#mmc1){ref-type="supplementary-material"}) and the BigDye Terminator Cycle Sequencing Kit (Thermo Fisher Scientific), on an ABI PRISM 3130xl Genetic Analyzer (Thermo Fisher Scientific). For some cell clones, the nested PCR products were cloned and sequenced using a Zero Blunt TOPO PCR Cloning Kit for Sequencing (Thermo Fisher Scientific).

Production of Gene-KO Pig Fetuses by Somatic Cell Nuclear Transfer {#sec4.5}
------------------------------------------------------------------

SCNT of gene-KO cells was performed as described previously ([@bib15], [@bib19]), with slight modifications. In brief, nuclear donor cells were used for SCNT following cell-cycle synchronization through serum starvation for 2 days. A single donor cell was electrically fused with each enucleated cytoplast prepared from *in-vitro*-matured oocytes. The reconstructed embryos were electrically activated and cultured in porcine zygote medium-5 (\[PZM-5\], Research Institute for Functional Peptides, Yamagata, Japan) ([@bib43]) for 3 h in the presence of 5 μg/mL cytochalasin B and 500 nM scriptaid ([@bib44]), and embryos were then cultured with 500 nM scriptaid for another 12--15 h. After these treatments, the cloned embryos were cultured in PZM-5 under a humidified atmosphere of 5% CO~2~, 5% O~2~, and 90% N~2~ at 38.5°C. After reaching the morula stage (day 4), the embryos were cultured in PZM-5 supplemented with 10% FBS. Cloned embryos at days 1--2 or days 5--6 were surgically transferred to the oviducts or uterine horns, respectively, of estrus-synchronized recipients. SCNT embryos at the morula stage were used to generate chimeric embryos.

Production of Chimeric Pig Fetuses by Blastocyst Complementation {#sec4.6}
----------------------------------------------------------------

Lines of mutant fibroblast cells carrying the *PDX1*-KO, *PDX1/KDR*-KO, *SALL1*-KO, and *HHEX*-KO traits were employed for nuclear transfer to produce cloned host embryos. Cloned donor embryos were produced through nuclear transfer using female fibroblasts isolated from a pig carrying the huKO ([@bib20]) or Plum ([@bib37]) transgenes. In some experiments, the donor blastomeres carrying huKO transgene were prepared from *in-vivo*-derived or IVF-derived morulae that had been cryopreserved previously ([@bib18]). WT embryos were also used for complementing the *HHEX*-KO embryos.

Donor embryos at the morula stage (day 4) were de-compacted with 0.1 mM EDTA-2Na (in Ca^2+^/Mg^2+^-free PBS supplemented with 0.01% polyvinyl alcohol) for 20 min, followed by the removal of the zonae pellucidae via digestion with a 0.25% pronase solution (in PBS(−)). Blastomeres were isolated from the embryos by gentle pipetting using a finely drawn glass capillary. Host embryos at the morula stage were similarly de-compacted. Six to eight donor blastomeres were injected into the center of each host embryo through micromanipulation. The injected embryos were cultured *in vitro* for 24 or 48 h to obtain chimeric blastocysts. Developing blastocysts were surgically transferred to the uteri of estrus-synchronized recipients on day 5 or 6.

Detection of Chimerism and Genotyping of Fetuses Using PCR {#sec4.7}
----------------------------------------------------------

Genomic DNA was extracted from biopsy specimens from the fetuses employing a DNA extraction kit (DNeasy Blood & Tissue Kit, QIAGEN, Hilden, Germany). All chimeras were identified by the detection of host and donor embryo-derived sequences by PCR analysis using appropriate primers ([Table S2](#mmc1){ref-type="supplementary-material"}) and DNA sequence analysis.

In brief, to identify *PDX1*-KO ↔ *huKO* (or *Plum*) chimeras, nested PCR was conducted to detect sequences derived from the host embryos (*PDX1*-KO) and donor embryos (*huKO* or *Plum*), respectively.

To identify *PDX1*/*KDR*-KO ↔ *huKO* chimeras, *KDR*-KO mutant sequences (host embryo derived), were amplified by PCR, cloned, and sequenced as described above, in addition to the detection of the *PDX1*-KO mutant and *huKO* transgene sequences ([Table S2](#mmc1){ref-type="supplementary-material"}). For some chimeric fetuses, allele-specific PCR using Hi-Di DNA polymerase (myPOLS Biotec, Konstanz, Germany) was performed using allele-specific primers, which allowed to amplify the *KDR*-KO allele (host embryo derived) efficiently.

To identify *SALL1*-KO ↔ huKO chimeras, nested PCR was performed to detect host embryo-derived (*SALL1*-KO) cells. To detect *huKO* transgene sequence (donor embryo-derived) and amelogenin (*AMEL X* and *Y* for sex determination) sequences, nested PCR was performed as described previously ([@bib21]).

To identify *HHEX*-KO ↔ WT (or huKO) chimeras, DNA sequence analyses to detect both WT and *HHEX* sequences (donor embryo derived) and *HHEX*-KO mutant sequence (host embryo derived) were conducted. The target regions in the *HHEX* gene were amplified by PCR, cloned, and sequenced, as described above ([Table S2](#mmc1){ref-type="supplementary-material"}). Nested PCR was conducted to detect *huKO* (donor embryo derived) and amelogenin sequences.

Histological Analyses {#sec4.8}
---------------------

Histological examination of mutated and complemented organogenesis was performed on tissue samples from the *PDX1*-KO, *PDX1*/*KDR*-KO, *SALL1*-KO, *HHEX*-KO, and chimeric fetuses. Control tissues were obtained from age-matched male normal (WT) fetuses. Tissue samples were fixed for 24 h in a neutrally buffered paraformaldehyde solution (4%) and embedded in paraffin blocks. The sections were stained with H&E or analyzed immunohistochemically using secondary antibodies conjugated with horseradish peroxidase (DAB stain) or fluorescent labels.

The primary antibodies used in this study were anti-insulin (no. LS-C24686, LifeSpan BioSciences, WA), anti-glucagon (no. G2654), and anti-VEGFR2 (no. 2479, Cell Signaling Technology, MA), anti-PECAM-1 (no. sc-1506, Santa Cruz Biotechnology, TX), anti-CD34 (no. 250591, Abbiotec, CA), anti-CD45 (no. 60287-1-Ig, Proteintech, IL), anti-SALL1 (no. PP-K9814-00, Perseus Proteomics, Tokyo, Japan), anti-albumin (no. A100-110A, Bethyl Laboratories, TX), and anti-huKO (no. PM051M, Medical & Biological Laboratories, Nagoya, Japan). The isotype-specific secondary antibodies were anti-guinea pig IgG coupled to Alexa Fluor 488 (no. ab150185, Abcam, Cambridge, UK) and anti-rabbit IgG coupled to Alexa Fluor 594 (no. A21207, Thermo Fisher Scientific). After antibody treatment, the sections were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA) containing DAPI for nuclear counterstaining and observed by fluorescence microscopy (BZ-X710; Keyence, Osaka, Japan).
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